Affordable Access

Publisher Website

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Authors
Journal
Advances in Hematology
1687-9104
Publisher
Hindawi Publishing Corporation
Publication Date
Volume
2011
Identifiers
DOI: 10.1155/2011/656013
Keywords
  • Review Article
Disciplines
  • Medicine

Abstract

A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.

There are no comments yet on this publication. Be the first to share your thoughts.